NCT01005108

Brief Summary

Overall Objectives: The overarching goal is to compare the effectiveness of acupuncture and gabapentin to their respective placebo controls in the treatment of hot flashes in breast cancer patients. The investigators primary specific aim will focus on determining the magnitude of response to placebo acupuncture versus placebo pills on hot flashes (HFs).

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
120

participants targeted

Target at P50-P75 for phase_2

Timeline
Completed

Started Jan 2009

Longer than P75 for phase_2

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2009

Completed
10 months until next milestone

First Submitted

Initial submission to the registry

October 29, 2009

Completed
1 day until next milestone

First Posted

Study publicly available on registry

October 30, 2009

Completed
4.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 31, 2014

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 31, 2014

Completed
Last Updated

April 15, 2020

Status Verified

April 1, 2020

Enrollment Period

5.1 years

First QC Date

October 29, 2009

Last Update Submit

April 13, 2020

Conditions

Keywords

Hot Flashes for Breast Cancer Patients

Outcome Measures

Primary Outcomes (1)

  • Daily Hot Flash Diary (DHFD)-Primary Outcome (2 minutes per day)

    Daily starting from baseline until week 12 and again for one week at week 24.

Secondary Outcomes (10)

  • Demographics -Covariates

    5 minutes

  • Hot Flash Related Daily Interference Scale (HFRDIS)-Secondary outcome

    3 minutes

  • Pittsburgh Sleep Quality Index (PSQI) - Secondary outcome

    6 minutes

  • Brief Fatigue Inventory (BFI) - Secondary Outcome

    3 minutes

  • HADS - Secondary Outcome

    2 minutes

  • +5 more secondary outcomes

Study Arms (4)

placebo pill

EXPERIMENTAL
Drug: Gabapentin

placebo accupuncture

EXPERIMENTAL
Drug: Gabapentin

accupuncture

EXPERIMENTAL
Drug: Gabapentin

gabapentin

EXPERIMENTAL
Drug: Gabapentin

Interventions

Use of Gabapentin as a control intervention to evaluate the relative effects and adverse events of acupuncture for hot flashes

accupuncturegabapentinplacebo accupunctureplacebo pill

Eligibility Criteria

Age18 Years+
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Women 18 years or older with a history of Stage I, II or III breast cancer for at least 12 months.
  • Have been seen by an oncologist within the previous 6-month period and determined to be free of disease by clinical examination and history;
  • Experienced at least two hot flashes daily over the seven-day screening period as based on the Daily Hot Flash Diary.
  • Hot flashes have been present for at least a month before study entry.
  • Willing to use non-hormonal contraceptives during the duration of the study if patient is premenopausal.

You may not qualify if:

  • Having metastatic breast cancer ( IV)
  • Currently on chemotherapy or radiation therapy as adjuvant treatment
  • Started hormonal therapies such as tamoxifen or aromatase inhibitors within the last 4 weeks; or plan to change or terminate hormonal therapies in the next 14 weeks.
  • Started or changed with treatments for hot flashes, such as SSRIs or clonidine within the last 4 weeks; or plan to change or terminate these therapies in the next 14 weeks.
  • Current use of estrogen and/or progestin.
  • Pregnancy
  • Breast feeding
  • Bleeding disorder or current use of warfarin or heparin by patient history because of the use of needles.
  • Previous use of gabapentin for hot flashes.
  • Current use of any anti-convulsant.
  • Renal dysfunction defined as serum creatinine concentration above 1.25 times the upper limit of normal
  • Known allergy to gabapentin.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Abramson Cancer Center of the Unviersity of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States

Location

Related Publications (3)

  • Romero SAD, Li QS, Orlow I, Gonen M, Su HI, Mao JJ. Genetic predictors to acupuncture response for hot flashes: an exploratory study of breast cancer survivors. Menopause. 2020 Aug;27(8):913-917. doi: 10.1097/GME.0000000000001545.

  • Garland SN, Xie SX, Li Q, Seluzicki C, Basal C, Mao JJ. Comparative effectiveness of electro-acupuncture versus gabapentin for sleep disturbances in breast cancer survivors with hot flashes: a randomized trial. Menopause. 2017 May;24(5):517-523. doi: 10.1097/GME.0000000000000779.

  • Mao JJ, Bowman MA, Xie SX, Bruner D, DeMichele A, Farrar JT. Electroacupuncture Versus Gabapentin for Hot Flashes Among Breast Cancer Survivors: A Randomized Placebo-Controlled Trial. J Clin Oncol. 2015 Nov 1;33(31):3615-20. doi: 10.1200/JCO.2015.60.9412. Epub 2015 Aug 24.

MeSH Terms

Conditions

Hot Flashes

Interventions

Gabapentin

Condition Hierarchy (Ancestors)

Signs and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

AminesOrganic Chemicalsgamma-Aminobutyric AcidAminobutyratesButyratesAcids, AcyclicCarboxylic AcidsCyclohexanecarboxylic AcidsAcids, CarbocyclicCyclohexanesCycloparaffinsHydrocarbons, AlicyclicHydrocarbons, CyclicHydrocarbonsAmino AcidsAmino Acids, Peptides, and Proteins

Study Officials

  • Jun J Mao, MD, MSCE

    Abramson Cancer Center at Penn Medicine

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 29, 2009

First Posted

October 30, 2009

Study Start

January 1, 2009

Primary Completion

January 31, 2014

Study Completion

January 31, 2014

Last Updated

April 15, 2020

Record last verified: 2020-04

Locations